Influenza vaccination is the cornerstone of influenza prevention programs around the world, and inactivated influenza vaccines are the most commonly used in these programs. The effectiveness of inactivated influenza vaccines depends, in part, on the degree of matching between vaccine and circulating strains of influenza virus [1] . As the prevailing strains change over time, regular updates of the vaccine strains are necessary to maintain moderate to high vaccine effectiveness [2] . Twice a year, the World Health Organization (WHO) issues recommendations on the vaccine strains to be used in the northern hemisphere (NH) and southern hemisphere (SH) [3] .
In subtropical and tropical locations, influenza viruses circulate for prolonged periods each year [4] , but national authorities usually choose to use either NH or SH vaccine in their annual campaigns [5] [6] [7] . Because the immune responses to influenza vaccination may be weaker in older adults [8] and may wane within a year [9] [10] [11] , older adults who receive once-annual vaccination may not be as well protected during the period 6-12 months after vaccination, and a booster vaccination halfway through the year could sustain protection [12, 13] . On the other hand, there is growing evidence that immune responses to repeated vaccination can be blunted, particularly when antigens are unchanged in successive vaccines [14] [15] [16] [17] [18] [19] [20] , and cellular immunity could also be impaired [21, 22] . If blunted immune responses to influenza vaccination led to poorer clinical protection over time [23] , that could disadvantage recipients of twice-annual vaccination, in addition to the increased cost of such a strategy [13] .
In Hong Kong, a city in southern China with a subtropical climate, influenza epidemics often occur twice per year in the winter and summer, and in some years there can be elevated influenza activity for >9 months [4, 24, 25] . Older adults are included as a priority group for influenza vaccination, and the government subsidizes the cost in public and private outpatient clinics, with annual campaigns using NH inactivated influenza
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vaccines each autumn. In the winter of 2014-2015, a large influenza A(H3N2) epidemic occurred in Hong Kong with the A/ Switzerland/9715293/2013-like strain, which was antigenically mismatched with the A/Texas/50/2012-like virus included in the 2014-2015 NH vaccine. Local authorities consequently imported and administered the 2015 SH trivalent inactivated influenza vaccine (TIV), which included an updated and matching A/ Switzerland/9715293/2013-like strain [26] , primarily targeting older adults ≥75 years old with initial priority given to those ≥85 years of age. We therefore had an opportunity to evaluate the potential impact of twice-annual vaccination on immunity against influenza in older adults. The aim of our study was to assess the immunogenicity of the SH TIV among older adults in Hong Kong and its effect on the immunogenicity of subsequent NH quadrivalent inactivated influenza vaccine (QIV).
METHODS

Study Design
In the summer of 2015, we enrolled older adults who presented at public-sector outpatient clinics to receive the SH TIV. Older adults were eligible to participate in the study if they were ≥75 years of age attending public-sector outpatient clinics for routine appointments. We excluded older adults who were not competent to give their consent. Participants received vaccines procured and administered in the government vaccination campaign recommended by the WHO, including the trivalent formulation of the 2015 SH inactivated influenza vaccine (Vaxigrip, Sanofi Pasteur), and the quadrivalent formulation of the 2015-2016 NH inactivated influenza vaccine (Fluarix Tetra, GlaxoSmithKline) (Supplementary Table 1) .
We collected serum samples immediately before vaccination (day 0) and 30 days after vaccination (median, 29 days [range, 28-35 days] ) (group A1). The same blood collection schedule was repeated for those who were reenrolled in the subsequent 2015-2016 winter for receiving the NH QIV (group A2), and additional new enrollees who received the 2015-2016 NH QIV but had not received the 2015 SH TIV as single-dose comparison group (group B2). Group A2 included additional enrollees who had received the SH TIV but who had not been enrolled in group A1. In a subset (20%) of these participants, we collected additionally heparinized whole blood samples immediately before vaccination, and 7 and 30 days after vaccination.
Ethical Approval
The study received ethical approval from the Institutional Review Board of the Hospital Authority/Hong Kong West Cluster. Written informed consent was obtained from participants. Upon collection, blood samples were stored at 2°C-8°C immediately and delivered to a central laboratory within 2 days for serum extraction, and stored at -80°C prior to testing. Sera were tested in parallel for humoral immune responses against the vaccine strains by the hemagglutination inhibition (HAI) assay [27] , and by a newly standardized lectin-based neuraminidase inhibition (NAI) assay [28] . Egg-based virus antigens were prepared following the standard WHO reagent preparation protocols. The HAI assay was carried out using turkey red blood cells with the relevant in-house serum controls in place. Sera were tested in serial doubling dilutions starting at 1:10, and the antibody titer was taken as the reciprocal of the greatest dilution that gave a positive result.
The ability of plasma to bind influenza proteins and activate antibody-dependent cell-mediated cytotoxicity (ADCC) function of natural killer (NK) cells was assessed in a previously described plate-style flow cytometry assay [29, 30] . Plate-bound recombinant HA protein representing the vaccine was used for A/California/07/2009(H1N1) and A/Switzerland/9715293/2013(H3N2) (Sinobiological).
Intracellular Cytokine Staining for Influenza-Specific T Cells
Peripheral blood mononuclear cell (PBMC) fractionation was done on heparinized blood samples by density gradient centrifugation within 12 hours of collection and stored in liquid nitrogen for batch analysis. We determined CD4 and CD8 T-cell responses against whole A(H1N1) and A(H3N2) viruses by interferon gamma (IFN-γ) production by intracellular cytokine staining at days 0, 7, and 30, representing baseline, acute peak, and memory responses, respectively. PBMCs were thawed in complete RPMI (with Benzoase, Merck; 5000 U), 1 × 10 6 PBMCs were stimulated with a multiplicity of infection = 4 of live virus representing the vaccine strains A/California/07/2009(H1N1) and A/Switzerland/9715293/2013(H3N2) for 6 hours in the presence of recombinant human interleukin 2 (IL-2) (Roche), LEAF CD49d, and CD28 (BioLegend). Then, brefeldin A, monensin, and antihuman CD107a-Pacific blue were added for a further 16 hours. Following stimulation, cells were stained for live/dead (Zombie-NIR), then in fluorescent activated cell sorting buffer (phosphate-buffered saline with 10% fetal bovine serum, 0.1% sodium azide) for a panel of antihuman surface markers: CD3-PETexasDazzle, CD4-BV605, CD8-AF700, dump (CD19/CD16/CD56-BV510), CD45RA-APC, CCR7-PerCPCy5.5, and CCR5-PE (BioLegend). Cells were then fixed with BD Cytofix/Cytoperm, and intracellular staining in BD PermWash buffer for antihuman IFNγ-fluorescein isothiocyanate and IL-2-phycoerythrin Cy7. Samples were acquired by flow cytometry on an LSR Fortessa and analyzed with FlowJo software. Background cytokine production was determined from no virus stimulation of PBMCs.
Statistical Analysis
The outcome measures were assessed in each group to estimate the immunogenicity of the 2015 SH TIV and 2015-2016 NH QIV. We estimated the geometric mean titer (GMT) of HAI titers pre-and postvaccination (ie, prevaccination and 1 month postvaccination), and the proportion of participants with postvaccination HAI titer ≥40, a threshold that is considered to be associated with at least 50% protection from influenza virus infection [31] . For NAI titers, we examined pre-and postvaccination GMTs. When estimating GMTs, we imputed 5 for titers <10, and 2560 for titers ≥1280.
We then compared GMTs following receipt of 2015-2016 NH QIV between participants who had received the 2015 SH TIV compared to those who had not. We estimated a priori that 400 older adults in each group in the final analysis would be sufficient to detect a ≥10% difference in the prevalence of titers ≥40 between these 2 groups with 5% significance level and 80% power. We performed stratified analyses to account for baseline differences between groups and used log-linear regression models to examine correlates of postvaccination GMTs. The magnitude of IFN-γ + influenza-specific T cells within each group at day 7 and 30 were compared with the respective day 0 response using Kruskal-Wallis rank-sum tests, with analyses restricted to individuals who provided all 3 samples. The end point 50% concentration of serum concentration for 50% of maximum NK cell activation vs 1:20 serum dilution was determined by best fit of nonlinear log regression analysis.
RESULTS
From May through July 2015, we approached 1684 older adults and finally enrolled 470 who received SH TIV (group A1) in 4 public outpatient clinics. The most frequent reasons for refusal to participate were inability to provide consent, unwillingness to provide blood samples, and lack of interest in the study. Between October and December 2015, we approached 5224 older adults and enrolled 827 who received the 2015-2016 NH QIV (group A2), and 408 participants who received NH QIV only (group B2) ( Figure 1 ). We included 1297 vaccination events in 978 participants in this study (Figure 1 ). Participants in group A2 were 3 years older on average and more likely to have received influenza vaccination in the prior 2 years than those in group B2 (Table 1 ). Because responses varied by age, we stratified the serologic analyses into 3 age groups: 75-79 years, 80-84 years, and ≥85 years. HAI titers were determined against both influenza A vaccine strains before and after receiving 2015 SH TIV in group A1 and 2015-2016 NH QIV in groups A2 and B2 (Figure 2) . In group A1, GMTs rose by factors of 1.8-3.4 with the largest fold rise against the updated A/Switzerland/9715293/2013 (H3N2)-like strain (Figure 2 ). In groups A2 and B2 within each age group, the GMTs against A(H1N1) and A(H3N2) rose after vaccination, with group B2 starting from a lower baseline and rising to a larger postvaccination GMT than group A2 (Figure 2 ). Similar patterns were observed for influenza B virus within each age group, where postvaccination GMTs after receipt of the 2015-2016 NH QIV were mostly lower in the group that had received the 2015 SH TIV (Figure 3 ).
The differences between groups A2 and B2 were maintained after adjustment for age, sex, and prior vaccination with the 2014-2015 NH vaccine (Table 2) , with group A2 having significantly lower postvaccination GMTs against A(H3N2), B/ Yamagata, and B/Victoria strains compared to group B2. A pattern consistent with the GMT changes was also noted in the increase of the proportion of participants reaching titers ≥40 postvaccination (Table 3) , with more participants in group B2 compared to group A2 reaching this threshold against A(H1N1), A(H3N2), and B/Yamagata, which were included in both the 2015 SH TIV and the 2015-2016 NH QIV. The proportion of participants in group A1 with titers ≥40 against A/ Switzerland/9715293/2013(H3N2) increased from 58.8% to 86.1% after receiving 2015 SH TIV (Table 3) .
NAI antibody titers were determined against influenza A(H1N1) and A(H3N2) before and after receiving 2015 SH TIV in group A1, and 2015-2016 NH QIV in groups A2 and Figure 1 . Flowchart of participants in the study. Among all participants enrolled, 49 withdrew after enrollment and vaccination and prior to the postvaccination blood draw. The reasons for withdrawal included being unwell to return for follow-up (n = 14), afraid of blood taking (n = 12), hospitalized (n = 9), traveling overseas (n = 6), unwilling to participate further (n = 5), or failed to be reached despite repeated attempts (n = 3). Abbreviations: IIV, inactivated influenza vaccine; NH, northern hemisphere; SH, southern hemisphere. Figure 1 ). There was no significant difference in prevaccination or postvaccination GMTs by NAI for all 3 groups. Furthermore, ADCC antibodies were not boosted by vaccination and there was no measurable difference to the magnitude of the response to the ADCC antibodies generated by the novel H3N2-Switzerland vaccine component or in their avidity (Supplementary Appendix Figure 2) .
B2 (Supplementary Appendix
Analysis of cellular immunity was performed to determine the immunological effect of twice-annual vaccination. In group A1, there was no significant differences postvaccination for H1N1-specific CD4 or CD8 T cells, while memory H3N2-specific CD4 T cells at day 30 were significantly increased by vaccination (Figure 4) . However, the winter NH vaccination showed significantly reduced T-cell responses across groups A2 and B2. Acute day 7 H1N1-and H3N2-specific CD4 and CD8 T-cell responses were significantly reduced in group A2 (Figure 4) . Furthermore, in the subset of participants who provided longitudinal samples for analysis in groups A1 and A2, there was a significantly lower H3N2-specific CD4 T-effector memory (CCR7 -CD45RA -) response at day 30 (P = .002) ( Figure 4E ).
DISCUSSION
We found that older adults who received the 2015 SH TIV had improved protection against the prevalent A/Switzerland/9715293/2013(H3N2) strain in the summer of 2015, as indicated by the significantly higher postvaccination HAI titers in group A1 (Figure 2) , and >25% increase of participants with antibody titers ≥40 after vaccination (Table 3) . Consistently, within each age stratum, group A2 tended to have higher GMTs by HAI than group B2 prior to receipt of the 2015-2016 NH QIV (Figures 2 and 3) , and a higher proportion with antibody titers ≥40 prior to receipt of the 2015-2016 NH QIV against A(H1N1), A(H3N2), and B/Victoria (Table 3) .
However, in the subsequent winter, we found evidence of reduced responses to the 2015-2016 NH QIV in those in group A2 who had received the 2015 SH TIV, compared to those in group B2 who had not (Figures 2 and 3) . Specifically, despite starting with higher prevaccination GMTs by HAI, group A2 had weaker rises in HAI titers and significantly lower postvaccination GMTs by HAI than group B2 for A(H3N2), B/Yamagata, and B/Victoria (Table 3) . A lower proportion of participants in group A2 had titers ≥40 to B/Yamagata after receipt of the 2015-2016 NH QIV (Table 3) . A blunted response to repeated vaccination with the same vaccine components was predicted by the antigenic distance hypothesis, that some of the antigen in the most recent vaccine will be partially eliminated by preexisting cross-reactive antibody from the prior vaccination leading to reduced responses [15, 23] . This phenomenon has also been shown in healthcare workers who received repeated annual influenza vaccination [19] .
Nevertheless, vaccination for 2015-2016 winter did improve GMTs in participants in our study in the group who received the 2015 SH TIV, with increases in the proportion that had titers ≥40 by 6% to 21% from day 0 to day 30 (Table 3) . This implies that, despite a reduced response, the NH QIV still improved overall protection levels in older adults who had received SH TIV.
Whereas influenza vaccination led to significant increases in GMTs measured by the HAI assay (Figures 2 and 3 ; Table 3 ), there were no significant increases in GMTs measured by the NAI assay (Supplementary Appendix Figure 1 ). The subunit inactivated influenza vaccine is purified and includes a defined amount of hemagglutinin protein and a very small amount of neuraminidase protein. Neuraminidase content was not determined in our study; however, no differences in NAI GMTs were observed between A1 (Vaxigrip TIV) and B2 (Fluarix Tetra QIV). As NAI titers have been associated with protection [32] , we infer no increased NAI protective benefit from twice-annual vaccination.
Overall, we found that ADCC antibodies had higher magnitude toward the pandemic A/California/07/2009(H1N1) virus than the A/Switzerland/9715293/2013(H3N2) virus. It is most likely that group A1 participants experienced a primary exposure to A/Switzerland/9715293/2013 (H3N2) virus, but no significant boosting effects were seen (Supplementary Appendix Figure 2 ), which may be attributed to cross-reactivity with H3N2 viruses that circulated previously and/or an immune ceiling threshold. There was no boosting effect on response magnitude or affinity attributed to biannual vaccination against the A/Switzerland/9715293/2013(H3N2) virus. This is the first report of direct measurements of vaccine effects on T-cell immunity for twice-annual vaccination. Overall, we showed small but statistically significantly reduced T-cell responses postvaccination in a subset of participants in groups A2 and B2 against some strains (Figure 4) . Participants who received both SH TIV and NH QIV (group A2) had reduced CD4 and CD8 T-cell responses against both the H1N1 and H3N2 viruses at day 7 and 30 postvaccination. This could , denoted as T-effector memory, showed significant changes postvaccination (E), whereas other subsets and CD8 T cells had no differences. Data are presented as percentage IFNg+ of CD4 or CD8 T cells at day 0, day 7 and day 30; mean differences from day 0 that were statistically significant by Kruskal Wallis tests are indicated. The experiment was repeated twice, using 2 different sets of participants. Abbreviation: IFN, interferon.
reflect a recruitment of a robust response to the lymph nodes or tissues [33] , or diminished T-cell response overall, and this unknown is a limitation of human studies on peripheral blood. However, our results indicate that twice-annual vaccination may reduce the magnitude of T-cell memory responses, particularly CD4 effector memory responses. Considering the half-life of T cells, estimated at 1-5 years [34] , that they can be detected for the lifetime of an individual [35] , and their recognition of conserved influenza epitopes [36] , twice-annual vaccination does not appear to have a likely benefit to T-cell responses.
There are some limitations to our study. First, this was an observational study, and there may have been other systematic differences between groups in addition to the difference in age that we identified. There was no comparator for group A1, although we did collect sera to assess prevaccination titers in this group that serve as a comparison. Second, participants in this study were very old adults, with the majority in groups A1 and A2 being >80 years of age. Our results might not generalize to adults between 65 and 74 years of age, or younger adults. Third, this study was designed to assess the immunogenicity of influenza vaccination over only 1 year, and the vaccine strains did not change (Supplementary Appendix Table 1 ). As the circulating strains of seasonal influenza change over time, a longer-term study would be valuable to investigate how changes in antigens and circulating strains contribute to the boosting and blunting of immune responses to influenza vaccination [15] . We did not have detailed information on prior vaccination history, and participants in our study could have received multiple prior vaccinations. Finally, we were not able to study vaccine effectiveness for protection from infection in this study due to a relatively smaller sample size. While HAI titers are correlated with clinical protection [31, 37] , other mechanisms may also play a role in the immunity conferred by influenza vaccination.
In conclusion, in this study of immune responses following twice-annual vaccination with SH and NH formulations compared to once-annual vaccination with the NH formulation in older adults, we found that NH QIV improved GMTs regardless of prior receipt of SH TIV, although there was some reduction in immune responses to subsequent NH QIV in the twice-annual vaccination group. Based on HAI titers, protection during the summer did appear to be higher for the twice-annual vaccination group that received SH TIV. Deciding whether to adopt twice-annual vaccination for older adults in the future may depend on predicted patterns in influenza circulation as well as appropriate vaccine availability [13] , and our study highlights both the potential advantages and disadvantages of such an approach.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
